Ranbaxy, Virchow Launch Bonista Generic In India
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and Virchow Biotech have launched a generic version of Bonista (teriparatide) injectable for treating osteoporosis. The drug was developed in part with aid from India's Department of Science and Technology. The treatment is based on the recombinant human parathyroid hormone. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.